


February 19, 2019

Agenda

- AMS Research Update
- Case Discussions
- Open Discussion



AMS Research Update

Chloe Bryson-Cahn, MD UW Medicine | Harborview Medical Center chloebc@uw.edu

7 vs. 14 days for uncomplicated GNR bacteremia

- Non-inferiority RCT not blinded
- Inclusion: GNR bacteremia, stable
- Exclusion:
 - uncontrolled focus
 - polymicrobial cx
 - specific pathogens (Salmonella, Brucella)
 - significant immunosuppression
- Source: urinary (68%), abd (12%), CVC (7%)
- Pathogen: Enterobacteriaceae (90%)



7 vs. 14 days for uncomplicated GNR bacteremia

Patients with Uncomplicated GNR Bacteremia on day 7 afebrile + hemodynamically stable x 48 hours

RANDOMIZATION

7 days of Abx 306 pts 14 days of Abx 298 pts

90 d Composite Outcome:


46%

mortality, clinical failure, readmission, extended hospitalization



RD: -2.6%, 95% CI -10.5% to 5.3%

7 vs. 14 days for uncomplicated GNR bacteremia







Oral Abx for Bone & Joint Infxn

- Non-inferiority RCT not blinded
- Inclusion: adults with bone and joint infections
- Initial 6 weeks of treatment randomized to IV or oral; antibiotic choice left to the ID clinician
- Infection details:
 - Chronic osteo with debridement (30%), implant debrided and retained (23%), ortho device removed (16%), prosthetic joint implant removes (12%)
 - S. aureus, CoNS, Strep; Gram negatives ~15%



Oral Abx for Bone & Joint Infxn








Li, NEJM 2019

Oral Abx for Bone & Joint Infxn



Risk difference oral v. IV: -1.4%; 90% CI, -5.6% to 2.9%

Treatment (Comp	lications
-------------	------	-----------


19%	Early treatment change	13%	P=0.006
9%	Catheter issues	1%	P<0.001

Pre-op ASB: Screen and Treat?

- Retrospective cohort study within the VA
- Inclusion: pts who had surgery & pre-op Urine Cx
 - Cardiac, orthopedic, vascular
- ID clinician review of complete medical records
- Male predominant population
- Patients with ASB were more likely to be
 - Female, older, DM
- 2 cases of ASB and SSI organism match (S. aureus)



Pre-op ASB: Screen and Treat?




Water to Prevent Recurrent UTI

- RCT, unblinded
- Inclusion:
 - Premenopausal women with recurrent cystitis
 - Baseline fluid intake < 1.5 L per day
- Women were randomized to increase water intake
 - Given 3 x 500mL bottles with instructions to drink throughout the day
 - Called monthly



Water to Prevent Recurrent UTI

Women with recurrent UTI and baseline low fluid intake



Take Aways

- Uncomplicated GNR bacteremia: treat for 7 days
- Oral antibiotics for bone and joint infections are an appropriate treatment option with fewer treatment associated complications
- Screening for and treating/prophy for pre-op ASB: doesn't reduce SSI
- Increase water intake (1.5 L) in premenopausal women with recurrent cystitis to decrease frequency of episodes and decrease abx use



Citations

- Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, Neuberger A, Ghanem-Zoubi N, Santoro A, Eliakim-Raz N, Pertzov B. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. Clinical Infectious Diseases. 2018 Dec 11.
- Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, Lipsky BA, Hughes HC, Bose D, Kümin M, Scarborough C. Oral versus intravenous antibiotics for bone and joint infection. New England Journal of Medicine. 2019 Jan 31;380(5):425-36.
- Salazar JG, O'brien W, Strymish JM, Itani K, Branch-Elliman W, Gupta K. Association of Screening and Treatment for Preoperative Asymptomatic Bacteriuria With Postoperative Outcomes Among US Veterans. JAMA surgery. 2018 Dec 12.
- Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, Lotan Y. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA internal medicine. 2018 Nov 1;178(11):1509-15.

